This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Using data from six clinical trials, researchers extended a pharmacokinetic model to describe oral semaglutide absorption, distribution, and elimination. The key finding is that oral bioavailability is remarkably low at just 0.8% under recommended dosing conditions (30 minutes fasting, taken with 120 mL or less of water).
Fasting longer after taking the pill increased how much drug got absorbed. Drinking more water decreased absorption. Body weight also affected exposure levels.
The day-to-day variation in how much drug gets absorbed from each individual pill was very high at 137%. However, because semaglutide has a long half-life and is taken daily, this variation smooths out to just 33% at steady state (when levels stabilize after days of dosing).
There was no significant difference in oral bioavailability between healthy people and those with type 2 diabetes.
Why it matters
Understanding why oral semaglutide has such low bioavailability and high variability helps explain its strict dosing requirements. It also reassures that despite wild day-to-day swings in absorption, the drug still reaches consistent therapeutic levels with daily dosing.
The numbers in context
0.8% oral bioavailability; 137% within-subject daily variability; 33% at steady state; 5-10 mg doses; 30-min fasting recommended
How the study worked
Researchers used a previously developed two-compartment pharmacokinetic model from subcutaneous and intravenous semaglutide data. They extended it with data from six oral semaglutide trials in healthy volunteers and people with kidney or liver impairment. Doses ranged from 5-10 mg. A separate analysis used data from a type 2 diabetes trial. The model was estimated using population pharmacokinetic methods.
Who was studied
Healthy volunteers and people with type 2 diabetes, renal, or hepatic impairment (human)
What this study cannot tell us
The model is based on clinical trial data where patients followed strict dosing instructions. Real-world adherence to the 30-minute fasting requirement and water restrictions may be lower, potentially reducing effectiveness. The study did not model food effects (eating too soon). Only doses up to 10 mg were studied; the 14 mg clinical dose was not included in all analyses.
Read the original research
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials.
Clinical pharmacokinetics, 60(10), 1335-1348
Citation
Overgaard, Rune V; Navarria, Andrea; Ingwersen, Steen H; Bækdal, Tine A; Kildemoes, Rasmus Juul. (2021). Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials.. Clinical pharmacokinetics, 60(10), 1335-1348. https://doi.org/10.1007/s40262-021-01025-x